-
Diagnostics World | Capstan Therapeutics is advancing CPTX2309, their lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders; Clasp is developing modular T cell engagers tailored to each patient’s immune system that are directed to common oncogenic driver mutations; X-Therma plan to scale global commercial operations and facilitate progression into the clinical stage with FDA Breakthrough Device status, aimed at significantly increasing organ availability for transplantation by overcoming time-sensitive limitations; and more.
Mar 27, 2024
-
Diagnostics World | Capstan Therapeutics is advancing CPTX2309, their lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders; Clasp is developing modular T cell engagers tailored to each patient’s immune system that are directed to common oncogenic driver mutations; X-Therma plan to scale global commercial operations and facilitate progression into the clinical stage with FDA Breakthrough Device status, aimed at significantly increasing organ availability for transplantation by overcoming time-sensitive limitations; and more.
Mar 26, 2024
-
Diagnostics World | The single biggest risk factor for autoimmune disease is being biologically a female and many explanations have been proposed as to why that is, among them sex hormones and the X chromosome with its large number of immune-related genes.
Mar 21, 2024
-
Diagnostics World | When it comes to research on amyotrophic lateral sclerosis (ALS), every stakeholder—most especially patients—knows time is of the essence. From diagnosis to death, life expectancy from the debilitating neuromuscular disease can be two years or less.
Mar 20, 2024
-
Diagnostics World | Scientists in the Georgia Tech Integrated Cancer Research Center (ICRC) are proposing a new, more realistic approach to diagnosing cancer that provides a probabilistic statement about the likelihood of developing it, much like how cholesterol tests are used to assess heart disease risk. Probabilities are based on an individual’s metabolic profile and the first population group to be targeted are women at high risk for ovarian cancer.
Mar 19, 2024
-
Diagnostics World | Scientists from a trio of countries are calling for a new, more comprehensive way of classifying Parkinson’s disease for diagnostic research purposes that considers an individual’s biology. The disorder might thereby be detected before patients have any symptoms, as is now the case for cancer and diabetes.
Mar 14, 2024